Status:
COMPLETED
Monitoring of COVID-19 Seroprevalence Among GHdC Staff Members
Lead Sponsor:
Grand Hôpital de Charleroi
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Grand Hôpital de Charleroi (GHdC) had to organize the vaccination of its staff in December 2021 against SARS-CoV-2.On the sidelines of this vaccination campaign, the management committee agreed to doc...
Detailed Description
Grand Hôpital de Charleroi (GHdC) staff were exposed to the risk of SARS-CoV-2 infection during the first half of 2020: a seroprevalence survey, conducted in the summer of 2020, after the "first wave"...
Eligibility Criteria
Inclusion
- To be an employee or independent collaborator at the GHdC
Exclusion
- Refusal to take a blood test for anti-SARS-CoV-2 antibodies
- Regarding amendment 1:
- Members who did not receive the third dose of PFIZER vaccine (Comirnaty) during the GHdC vaccination campaign and who did not performed a blood test to measure anti-SARS-CoV-2 antibodies.
Key Trial Info
Start Date :
February 5 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2022
Estimated Enrollment :
4000 Patients enrolled
Trial Details
Trial ID
NCT04813497
Start Date
February 5 2021
End Date
April 30 2022
Last Update
June 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Grand Hôpital de Charleroi
Charleroi, Hainaut, Belgium, 6060